Apricus Biosciences Receives Notice of Issuance for First Prevonco(TM) Patent in the United States

cus Biosciences,

(http://www.apricusbio.com), announced today that the Company received an Issue Notification from the United States Patent and Trademark Office for U.S. Patent Application No. 12/138,603 entitled "Thiazole Compounds, and Compositions and Methods Using Same." This soon-to-be issued patent claims certain compositions and methods for inhibiting tumor growth related to PrevOnco™, Apricus Bio's proprietary Phase III-ready cancer treatment for patients with advanced, unresectable hepatocellular carcinoma ("HCC"), or liver cancer. When issued, the patent will provide patent protection into 2029 and will be the Company's first granted patent in the United States for PrevOnco™. The Company currently has two other PrevOnco™ patent applications pending in the United States. Worldwide, Apricus Bio has one granted patent for PrevOnco™ in Canada and 10 pending applications in Canada, China, European Union, Japan, Israel, Mexico, New Zealand, and South Korea. The Company is also developing oral PrevOnco™ applications that utilize its proprietary NexACT® technology platform to be used as the final product for the Phase III that is in discussion with the U.S. Food and Drug Administration ("FDA").